Next-Generation Antibody Market Research Report and Outlook by 2028

The worldwide market for next-generation antibodies is projected to grow from US$ 5,428.41 million in 2021 to US$ 12,050.13 million by 2028, reflecting a compound annual growth rate (CAGR) of 11.9% during the period from 2021 to 2028.

This expansion in the next-generation antibody therapeutics sector is primarily driven by the increasing prevalence of cancer and a heightened demand for effective treatments. Nevertheless, the growth of this market faces obstacles, particularly in the areas of manufacturing complexities and regulatory approval processes.

Next-generation antibodies are designed to be more targeted and effective compared to conventional monoclonal antibodies. The development of these advanced antibodies necessitates sophisticated engineering techniques to guarantee their stability, precise delivery to target sites, and reduced off-target effects.

The next-generation antibody market is categorized based on therapeutic areas, technological advancements, and geographical regions. In terms of therapeutic areas, the market is divided into oncology and autoimmune/inflammatory conditions, with oncology holding a significant share in 2021 and anticipated to experience a faster growth trajectory. From a technological perspective, the market is segmented into antibody-drug conjugates (ADCs), bispecific antibodies, Fc-engineered antibodies, antibody fragments and antibody-like proteins, as well as biosimilar antibody products. The ADC segment is expected to lead the market, while bispecific antibodies are projected to witness the most rapid growth due to their increasing application in treating a variety of diseases worldwide.

Antibody-drug conjugates (ADCs) are anticipated to dominate the next-generation antibody market for several compelling reasons. Firstly, ADCs represent a groundbreaking class of next-generation antibodies that can deliver potent cytotoxic agents directly to cancer cells, thereby minimizing harm to healthy tissues and reducing side effects. This targeted delivery system enhances treatment efficacy and improves patient outcomes. Secondly, ADCs have demonstrated significant effectiveness in treating various forms of cancer, including breast cancer, lymphoma, and leukemia, which has led to a notable increase in their demand and integration into treatment protocols. Furthermore, major pharmaceutical companies are heavily investing in the research and development of ADCs, resulting in a robust expansion of their product pipelines. This intensified focus on innovation is expected to further accelerate the growth of the ADC segment within the next-generation antibody market. The distinct advantages of ADCs over traditional chemotherapy, coupled with the rising investments in their development, position them as a key segment in the next-generation antibody landscape, making it likely that they will capture the largest market share.

The analysis of the next-generation antibody market was conducted using a combination of primary and secondary research sources, including data from Globocan, the World Health Organization (WHO), the International Agency for Research on Cancer (IARC), and the Organization for Economic Co-operation and Development (OECD).